Int J Biol Sci 2013; 9(9):947. doi:10.7150/ijbs.9.947
A Novel Aurora-A Inhibitor, BPR1K0609S1, Sensitizes Colorectal Tumor cells to 5-Fluorofracil (5-FU) Treatment
1. Department of Medicine, NUHS, Pritzker School of Medicine, The University of Chicago, Evanston, USA.
2. Institute of Biotechnology and Pharmaceutical Research National Health Research Institutes, Miaoli, Taiwan 305.
3. Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, USA.
Shionome Y, Lin WH, Shiao HY, Hsieh HP, Hsu JTA, Ouchi T. A Novel Aurora-A Inhibitor, BPR1K0609S1, Sensitizes Colorectal Tumor cells to 5-Fluorofracil (5-FU) Treatment. Int J Biol Sci 2013; 9(9):947. doi:10.7150/ijbs.9.947. Available from http://www.ijbs.com/v09p0947.htm
Corrected-article in Int J Biol Sci, Volume 9, 403
In our above article of Int J Biol Sci 2013; 9(4): 403-411, we would like to clarify that control data using HCT116 and its derivative cells are shared with our PloS ONE paper . Both papers are about the chemosensitivity of cells to several different Aurora-A inhibitors. We are sorry for the confusion.
1. Shionome Y, Yan L, Liu S, Saeki T, Ouchi T. Integrity of p53 Associated Pathways Determines Induction of Apoptosis of Tumor Cells Resistant to Aurora-A Kinase Inhibitors. PLoS ONE. 2013;8(1):e55457
Corresponding author: Toru Ouchi, Department of Cancer Genetics, Roswell Park Cancer Institute, Elm and Carlson Streets, Buffalo, NY 14263, USA. Phone: (716) 845-7173. Fax: (716) 845-1698 Email: Toru.Ouchiorg.